Trial Outcomes & Findings for Clarithromycin Mechanisms in Hypersomnia Syndromes (NCT NCT04026958)
NCT ID: NCT04026958
Last Updated: 2026-08-07
Results Overview
The Epworth Sleepiness Scale asks participants to respond to 8 scenarios with how likely they are to fall asleep on a 4-point scale where 0 = "would never doze" and 3 = "high chance of dozing". Total scores range from 0 to 24 where higher scores indicate a higher chance of falling asleep during daytime activities. The change in ESS score is obtained by subtracting the total score at Day 14 from the baseline score. Scores above 0 mean that the mean score at Day 14 was lower than the mean score at Baseline, indicating less sleepiness.
COMPLETED
PHASE2
83 participants
Day -1, Day 14
2026-08-07
Participant Flow
Participants were recruited from the Emory Sleep Center in Atlanta, Georgia in the United States. Participant enrollment began September 4, 2019 and all follow-up assessments were completed by June 18, 2025.
Participant milestones
| Measure |
Clarithromycin
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Placebo
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Overall Study
STARTED
|
40
|
43
|
|
Overall Study
COMPLETED
|
37
|
42
|
|
Overall Study
NOT COMPLETED
|
3
|
1
|
Reasons for withdrawal
| Measure |
Clarithromycin
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Placebo
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Overall Study
Adverse Event
|
2
|
0
|
|
Overall Study
Lost to Follow-up
|
0
|
1
|
|
Overall Study
Positive coronavirus disease 2019 (COVID-19) test in asymptomatic participant
|
1
|
0
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Clarithromycin
n=40 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Placebo
n=43 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Total
n=83 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
32.6 years
STANDARD_DEVIATION 9.7 • n=40 Participants
|
34.8 years
STANDARD_DEVIATION 11.3 • n=43 Participants
|
33.7 years
STANDARD_DEVIATION 10.5 • n=83 Participants
|
|
Sex/Gender, Customized
Male
|
7 Participants
n=40 Participants
|
8 Participants
n=43 Participants
|
15 Participants
n=83 Participants
|
|
Sex/Gender, Customized
Female
|
32 Participants
n=40 Participants
|
35 Participants
n=43 Participants
|
67 Participants
n=83 Participants
|
|
Sex/Gender, Customized
Non-binary
|
1 Participants
n=40 Participants
|
0 Participants
n=43 Participants
|
1 Participants
n=83 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Region of Enrollment
United States
|
40 Participants
n=40 Participants
|
43 Participants
n=43 Participants
|
83 Participants
n=83 Participants
|
|
Type of Hypersomnia
Narcolepsy Type 1
|
6 Participants
n=40 Participants
|
3 Participants
n=43 Participants
|
9 Participants
n=83 Participants
|
|
Type of Hypersomnia
Narcolepsy Type 2
|
10 Participants
n=40 Participants
|
9 Participants
n=43 Participants
|
19 Participants
n=83 Participants
|
|
Type of Hypersomnia
Idiopathic Hypersomnia
|
17 Participants
n=40 Participants
|
21 Participants
n=43 Participants
|
38 Participants
n=83 Participants
|
|
Type of Hypersomnia
Subjective Sleepiness
|
7 Participants
n=40 Participants
|
10 Participants
n=43 Participants
|
17 Participants
n=83 Participants
|
|
Epworth Sleepiness Scale Score
|
15.8 score on a scale
STANDARD_DEVIATION 3.4 • n=38 Participants • Two participants in the Clarithromycin group did not complete this assessment at Baseline.
|
14.9 score on a scale
STANDARD_DEVIATION 4.1 • n=43 Participants • Two participants in the Clarithromycin group did not complete this assessment at Baseline.
|
15.3 score on a scale
STANDARD_DEVIATION 3.8 • n=81 Participants • Two participants in the Clarithromycin group did not complete this assessment at Baseline.
|
|
Maintenance of Wakefulness Test (MWT) Mean Latency
|
17.9 minutes
STANDARD_DEVIATION 11.2 • n=40 Participants • One participant in the Placebo group did not complete this assessment at Baseline.
|
18.6 minutes
STANDARD_DEVIATION 12.8 • n=42 Participants • One participant in the Placebo group did not complete this assessment at Baseline.
|
18.3 minutes
STANDARD_DEVIATION 12.0 • n=82 Participants • One participant in the Placebo group did not complete this assessment at Baseline.
|
PRIMARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who completed the ESS during at least one study timepoint.
The Epworth Sleepiness Scale asks participants to respond to 8 scenarios with how likely they are to fall asleep on a 4-point scale where 0 = "would never doze" and 3 = "high chance of dozing". Total scores range from 0 to 24 where higher scores indicate a higher chance of falling asleep during daytime activities. The change in ESS score is obtained by subtracting the total score at Day 14 from the baseline score. Scores above 0 mean that the mean score at Day 14 was lower than the mean score at Baseline, indicating less sleepiness.
Outcome measures
| Measure |
Placebo
n=43 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=40 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Epworth Sleepiness Scale (ESS) Score
|
2.5 score on a scale
Standard Deviation 4.0
|
1.7 score on a scale
Standard Deviation 4.1
|
PRIMARY outcome
Timeframe: Day -1, Day 14The MWT polysomnographic procedure for sleep latency examines how well participants stay awake during several trials where participants relax in a quiet room for 40 minutes. One study found the mean sleep latency among persons without a sleep disorder to be 35.2 minutes. The change from baseline is calculated as baseline sleep latency minus sleep latency at Day 14, in minutes. Positive values result when the duration of sleep latency at Day 14 is lower than at Baseline.
Outcome measures
| Measure |
Placebo
n=43 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=40 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Maintenance of Wakefulness Test (MWT) for Sleep Latency
|
-1.1 minutes
Standard Deviation 8.2
|
1.2 minutes
Standard Deviation 7.6
|
PRIMARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who completed lumbar punctures at both timepoints. Some participants opted out of one or both lumbar punctures.
Cerebrospinal fluid (CSF) is drawn to determine the change in levels of GABA-A potentiation between the study arms. The difference between measured current with GABA alone and the current measured with GABA + CSF yields a measure of potentiation for each CSF sample in each condition. The change from baseline is calculated as the baseline value minus the value at Day 14.
Outcome measures
| Measure |
Placebo
n=15 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=14 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Gamma-aminobutyric Acid Receptor A (GABA-A) Potentiation
|
-5.1 percent potentiation
Standard Deviation 75.1
|
-56.5 percent potentiation
Standard Deviation 141.3
|
PRIMARY outcome
Timeframe: Day -2, Day 13Population: This analysis includes participants who completed the MRI at both timepoints; some participants completed just one MRI and some did not do an MRI at either timepoint.
The default mode network (DMN) consists of a group of highly correlated brain regions most active during quiet rest, while the task positive network (TPN) is the brain network activated for goal-directed tasks. DMN connectivity changes with sleep states and it is increasingly implicated in the symptomatology of sleepiness. During resting state, sleep deprived participants demonstrate reduced static connectivity with the DMN. Changes in DMN between the Baseline 1 (Day - 2) and Day 13 visits are compared between treatment groups, particularly using quasi-periodic patterns (QPPs), which interrogate network-level connectivity on a dynamic scale. Preservation of the temporal dimension provides more insight into how this spatiotemporal network propagates across condition and pathology. The DMN/TPN QPP correlation is reported.
Outcome measures
| Measure |
Placebo
n=32 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=28 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Default Mode Network (DMN) Connectivity
|
0.04 correlation of DMN and TPN QPPs
Standard Deviation 0.77
|
-0.06 correlation of DMN and TPN QPPs
Standard Deviation 0.86
|
PRIMARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of TNF-α between the study arms. TNF-α is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness.
Outcome measures
| Measure |
Placebo
n=40 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=36 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Tumor Necrosis Factor - Alpha (TNF-α)
|
-0.06 picograms per milliliter (pg/mL)
Standard Deviation 0.47
|
0.03 picograms per milliliter (pg/mL)
Standard Deviation 0.20
|
PRIMARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who provided a stool sample at each timepoint; some participants opted out of providing stool samples.
Changes in microbiome composition, as measured by alpha diversity using the Shannon Index, via 16S ribosomal ribonucleic acid (rRNA) sequencing results are compared between study arms. The Shannon Index measures both abundance and evenness of microbial species, values of 0 indicate that a community has only one species. The higher the value the higher the diversity of species in a particular community. Change from baseline is calculated by subtracting the Day 14 value from the value at Baseline. Numbers greater than 0 indicate that the Day 14 Shannon index value is lower than at Baseline.
Outcome measures
| Measure |
Placebo
n=21 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=16 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Gastrointestinal Microbiome Composition
|
0.03 unitless
Standard Deviation 0.18
|
-0.13 unitless
Standard Deviation 0.17
|
SECONDARY outcome
Timeframe: Day 1 through Day 14Population: Some participants did not complete the sleep log or did not complete the sleep log with sufficient details for analysis.
Participants log when they go to bed and when they wake up in order to calculate the number of minutes spent sleeping. The average duration of sleep across 14 days is compared between study arms.
Outcome measures
| Measure |
Placebo
n=29 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=20 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
On-Treatment Sleep Duration
|
479.9 minutes
Standard Deviation 59.5
|
493.2 minutes
Standard Deviation 81.4
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who completed the FSS at both study timepoints; some participants did not complete this assessment and participants with missing questionnaires at either timepoint were excluded.
Fatigue severity is measured with the Fatigue Severity Scale (FSS). The FSS is a 9-item instrument where responses are on a scale of 1 to 7 where 1 = "disagree" and 7 = "agree". Total scores range from 9 to 63 where higher scores indicate greater fatigue. The change in FSS score is obtained by subtracting the total score at Day 14 from the Baseline score. Scores above 0 signify that the mean score at Day 14 was lower than the mean score at Baseline, indicating decreased fatigue.
Outcome measures
| Measure |
Placebo
n=42 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=34 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Fatigue Severity Scale (FSS) Score
|
3.5 score on a scale
Standard Deviation 9.0
|
3.5 score on a scale
Standard Deviation 10.2
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who completed the MFI-20 at both study timepoints; some participants did not complete this assessment and participants with missing questionnaires at either timepoint were excluded.
The MFI-20 is a 20-item instrument assessing fatigue severity. Responses are on a 5-point scale where 1 = "yes, that is true" and 5 = "no, that is not true". Positively phrased items are reverse scored so that the total score ranges from 20 to 100 where higher scores indicate greater severity of fatigue. The change in MFI-20 score is obtained by subtracting the total score at Day 14 from the Baseline score. Scores above 0 signify that the mean score at Day 14 was lower than the mean score at Baseline, indicating decreased fatigue.
Outcome measures
| Measure |
Placebo
n=42 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=35 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Multidimensional Fatigue Inventory (MFI-20) Score
|
6.6 score on a scale
Standard Deviation 12.8
|
3.8 score on a scale
Standard Deviation 12.1
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who completed the SIQ at both study timepoints; some participants did not complete this assessment and participants with missing questionnaires at either timepoint were excluded.
The SIQ is an instrument with 21 items with responses on a 5-point scale where 1 = "not at all" and 5 = "all the time". Two additional questions relate to how much time it takes for the respondent to wake up in the morning. Total scores range from 21 to 105 and higher scores indicate increased difficulty from tiredness. The change in SIQ score is obtained by subtracting the total score at Day 14 from the baseline score. Scores above 0 signify that the mean score at Day 14 was lower than the mean score at Baseline, indicating reduced difficulty awakening.
Outcome measures
| Measure |
Placebo
n=42 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=35 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Sleep Inertia Questionnaire (SIQ) Score
|
11.7 score on a scale
Standard Deviation 16.7
|
9.3 score on a scale
Standard Deviation 17.7
|
SECONDARY outcome
Timeframe: Day 1 through Day 14Population: Some participants did not complete the sleep log or did not complete the sleep log with sufficient details for analysis of sleep inertia.
Sleep inertia is measured with a single item on a 10-point Likert scale asking participants how difficult it was for them to wake up in the morning, where 1 = "not difficult at all" and 10 = "very difficult". The average scores across 14 days are compared between study arms.
Outcome measures
| Measure |
Placebo
n=28 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=19 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
On-Treatment Sleep Inertia Likert Scale
|
5.8 units on a scale
Standard Deviation 2.0
|
6.3 units on a scale
Standard Deviation 2.2
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of IL-1α between the study arms. IL-1α is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in IL-1α is obtained by subtracting the IL-1α level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=39 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=36 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Interleukin 1 Alpha (IL-1α)
|
0.69 pg/mL
Standard Deviation 11.89
|
0.81 pg/mL
Standard Deviation 4.98
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of IL-1β between the study arms. IL-1β is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in IL-1β is obtained by subtracting the IL-1β level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=29 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=23 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Interleukin 1 Beta (IL-1β)
|
-0.005 pg/mL
Standard Deviation 0.19
|
-0.005 pg/mL
Standard Deviation 0.15
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of IL-2 between the study arms. IL-2 is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in IL-2 is obtained by subtracting the IL-2 level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=35 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=33 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Interleukin 2 (IL-2)
|
-1.26 pg/mL
Standard Deviation 4.08
|
1.32 pg/mL
Standard Deviation 7.03
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of IL-6 between the study arms. IL-6 is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in IL-6 is obtained by subtracting the IL-6 level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=41 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=33 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Interleukin 6 (IL-6)
|
-0.07 pg/mL
Standard Deviation 0.70
|
0.03 pg/mL
Standard Deviation 0.64
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of IL-8 between the study arms. IL-8 is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in IL-8 is obtained by subtracting the IL-8 level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=41 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=36 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Interleukin (IL-8)
|
0.56 pg/mL
Standard Deviation 2.75
|
0.72 pg/mL
Standard Deviation 2.86
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of IL-15 between the study arms. IL-15 is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in IL-15 is obtained by subtracting the IL-15 level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=41 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=36 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Interleukin (IL-15)
|
-0.12 pg/mL
Standard Deviation 0.74
|
-0.05 pg/mL
Standard Deviation 0.58
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of IL-18 between the study arms. IL-18 is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in IL-18 is obtained by subtracting the IL-18 level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=41 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=36 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Interleukin (IL-18)
|
46.8 pg/mL
Standard Deviation 118.8
|
17.9 pg/mL
Standard Deviation 118.0
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of TNF-β between the study arms. TNF-β is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in TNF-β is obtained by subtracting the TNF-β level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=41 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=35 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Tumor Necrosis Factor Beta (TNF-β)
|
-0.08 pg/mL
Standard Deviation 0.31
|
0.007 pg/mL
Standard Deviation 0.11
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who had two blood draws. Not all participants had blood drawn at each timepoint and some individual measures were out of range for the assay and were excluded.
Blood samples are used to determine the change in levels of INF-α2a between the study arms. INF-α2a is a soporific cytokine and a reduction in soporific cytokines is hypothesized to reduce daytime sleepiness. The change in INF-α2a is obtained by subtracting the INF-α2a level at Day 14 from the Baseline level.
Outcome measures
| Measure |
Placebo
n=17 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=14 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Interferon Alpha (INF-α2a)
|
-0.56 pg/mL
Standard Deviation 1.17
|
0.04 pg/mL
Standard Deviation 0.30
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who completed the questionnaire at both study timepoints; participants with missing questionnaires at either timepoint were excluded
The FOSQ is a 30-item instrument assessing how sleepiness impacts daily activities. There are five subscales assessing General Productivity, Activity Level, Vigilance, Social Outcomes, and Intimate and Sexual Relationships. Items are scored on a 4-point scale where 1 = extreme difficulty and 4 = no difficulty. Subscale scores are obtained by calculating the mean score for the items in that subscale and each can range from 1 to 4, where higher scores indicate less difficulty due to sleepiness. A total score is obtained by calculating the means of the subscale scores and multiplying that by the number of subscales with a score. The total score ranges from 5 to 20 and higher scores indicate less difficulty from sleepiness. The change in FOSQ score is obtained by subtracting the total score at Day 14 from the Baseline score. Scores below 0 signify that the mean score at Day 14 was higher than the mean score at Baseline, indicating reduced difficulty from sleepiness.
Outcome measures
| Measure |
Placebo
n=42 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=35 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Functional Outcomes of Sleep Questionnaire (FOSQ) Score
|
-1.2 score on a scale
Standard Deviation 2.5
|
-1.4 score on a scale
Standard Deviation 3.3
|
SECONDARY outcome
Timeframe: Day -1, Day 14Population: This analysis includes participants who completed the questionnaire at both study timepoints; participants with missing questionnaires at either timepoint were excluded
The HSI is a 9-item instrument assessing the severity of excessive sleepiness (hypersomnolence). Items are scored on a Likert scale where 0 = not at all and 4 = very much. Total scores range from 0 to 36 and higher scores indicate greater severity of symptoms of hypersomnia. The change from baseline is calculated as the baseline score minus the score at Day 14. The change in HSI score is obtained by subtracting the total score at Day 14 from the baseline score. Scores above 0 signify that the mean score at Day 14 was lower than the mean score at Baseline, indicating reduced severity of hypersomnia symptoms.
Outcome measures
| Measure |
Placebo
n=42 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=35 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in Hypersomnia Severity Index (HSI)
|
5.3 score on a scale
Standard Deviation 7.4
|
3.0 score on a scale
Standard Deviation 8.1
|
SECONDARY outcome
Timeframe: Day -2, Day 13Population: This analysis includes participants who completed the MRI at both timepoints; some participants completed just one MRI and some did not do an MRI at either timepoint.
For functional connectivity analyses, each functional scan is parceled into the 246 regions of interest (ROIs), spanning Yeo's 7 networks contained in the Brainnetome Atlas and mean timecourse is calculated for each group. Pearson correlations between each pair of ROIs are calculated, to determine the strength of functional connectivity between each pair of regions and inter/intra-network. This yields a functional connectivity matrix for each functional scan (at both a subject- and group-level). These correlation matrices are Fischer z-transformed and averaged across each condition to create a mean functional connectivity matrix for each condition. Here, the average default mode network (DMN) connectivity is reported. Z-scores have a mean of 0 and scores higher than 0 indicate increased functional connectivity. The change from Baseline is calculated by subtracting the Day 13 score from the score at Day -2. Values lower than 0 mean that the Day 13 score was higher than at baseline.
Outcome measures
| Measure |
Placebo
n=32 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=28 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in MRI Functional Connectivity
|
-0.03 z-score
Standard Deviation 0.08
|
-0.02 z-score
Standard Deviation 0.07
|
SECONDARY outcome
Timeframe: Day -2, Day 13Population: This analysis includes participants who completed the MRI at both timepoints and participated in the MRI tasks. Some participants completed just one MRI and some did not do an MRI at either timepoint; of those who did complete both MRIs, some did not complete the N-back tasks.
Participants complete a working memory task during functional magnetic resonance imaging (fMRI). The change in task performance is measured as accuracy during 3 different levels of back tasks (0-back, 1-back, and 2-back), from baseline to on-treatment (Day 13). The 0-back test has participants respond to a prespecified stimulus and is a control condition. The 1-back involves remembering and responding to a prior stimulus, while a stimulus two trials earlier is responded to with the 2-back. The change in the percentage of correct responses is obtained by subtracting the percentage at Day 14 from the Baseline percentage. Values below 0 signify that the mean percent accuracy at Day 14 was higher than the mean percent accuracy at Baseline, indicating increased accuracy.
Outcome measures
| Measure |
Placebo
n=26 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=21 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in MRI Task Performance - N-Back Accuracy
2-back
|
-0.08 percentage of correct responses
Standard Deviation 0.13
|
-0.005 percentage of correct responses
Standard Deviation 0.10
|
|
Change in MRI Task Performance - N-Back Accuracy
0-back
|
-0.09 percentage of correct responses
Standard Deviation 0.21
|
-0.01 percentage of correct responses
Standard Deviation 0.20
|
|
Change in MRI Task Performance - N-Back Accuracy
1-back
|
-0.09 percentage of correct responses
Standard Deviation 0.15
|
0.008 percentage of correct responses
Standard Deviation 0.17
|
SECONDARY outcome
Timeframe: Day -2, Day 13Population: This analysis includes participants who completed the MRI at both timepoints and participated in the MRI tasks. Some participants completed just one MRI and some did not do an MRI at either timepoint, of those who did complete both MRIs, some did not complete the all of the N-back tasks.
Participants complete a working memory task during functional magnetic resonance imaging (fMRI). he change in task performance is measured as reaction time during 3 different levels of back tasks (0-back, 1-back, and 2-back), from baseline to on-treatment (Day 13). The 0-back test has participants respond to a prespecified stimulus and is a control condition. The 1-back involves remembering and responding to a prior stimulus, while a stimulus two trials earlier is responded to with the 2-back. The change in the reaction time of responses is obtained by subtracting the time at Day 14 from the Baseline time. Scores above 0 signify that the mean time at Day 14 was lower than the mean time at Baseline, indicating faster reaction time.
Outcome measures
| Measure |
Placebo
n=26 Participants
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Clarithromycin
n=21 Participants
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
Change in MRI Task Performance - N-Back Reaction Time
0-back reaction time for correct responses
|
-3.5 milliseconds
Standard Deviation 37.3
|
-11.3 milliseconds
Standard Deviation 47.1
|
|
Change in MRI Task Performance - N-Back Reaction Time
1-back reaction time for correct responses
|
-6.9 milliseconds
Standard Deviation 28.9
|
14.4 milliseconds
Standard Deviation 50.7
|
|
Change in MRI Task Performance - N-Back Reaction Time
2-back reaction time for correct responses
|
0.06 milliseconds
Standard Deviation 59.2
|
-41.0 milliseconds
Standard Deviation 87.4
|
Adverse Events
Clarithromycin
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Clarithromycin
n=40 participants at risk
Participants in this study arm receive clarithromycin for 14 days. Clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
Placebo
n=43 participants at risk
Participants in this study arm receive a placebo to match clarithromycin for 14 days. A placebo to match clarithromycin is dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
|
|---|---|---|
|
General disorders
Headache, including post-lumbar puncture headache
|
17.5%
7/40 • Information on adverse events was collected beginning at the time individuals were randomized and continued through two weeks after discontinuing the study medication, up to 4 weeks.
|
16.3%
7/43 • Information on adverse events was collected beginning at the time individuals were randomized and continued through two weeks after discontinuing the study medication, up to 4 weeks.
|
|
Musculoskeletal and connective tissue disorders
Back soreness/pain, including post-lumbar puncture soreness
|
15.0%
6/40 • Information on adverse events was collected beginning at the time individuals were randomized and continued through two weeks after discontinuing the study medication, up to 4 weeks.
|
18.6%
8/43 • Information on adverse events was collected beginning at the time individuals were randomized and continued through two weeks after discontinuing the study medication, up to 4 weeks.
|
|
Gastrointestinal disorders
Any gastrointestinal symptoms
|
25.0%
10/40 • Information on adverse events was collected beginning at the time individuals were randomized and continued through two weeks after discontinuing the study medication, up to 4 weeks.
|
27.9%
12/43 • Information on adverse events was collected beginning at the time individuals were randomized and continued through two weeks after discontinuing the study medication, up to 4 weeks.
|
|
General disorders
Bad taste
|
20.0%
8/40 • Information on adverse events was collected beginning at the time individuals were randomized and continued through two weeks after discontinuing the study medication, up to 4 weeks.
|
0.00%
0/43 • Information on adverse events was collected beginning at the time individuals were randomized and continued through two weeks after discontinuing the study medication, up to 4 weeks.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place